Trump administration cancels $590 million Moderna contract for bird flu vaccine, citing safety concerns with mRNA technology despite promising clinical results.
Key Takeaways
- The Department of Health and Human Services (HHS) has terminated Moderna’s $590 million contract for developing an H5N1 bird flu vaccine using mRNA technology.
- Despite positive Phase 1/2 clinical trial results showing 97.8% of participants achieving protective antibody responses, HHS cited concerns about mRNA technology’s safety profile.
- Moderna plans to explore alternative development paths for the vaccine program despite the loss of government funding.
- Public health experts have criticized the decision, warning it could leave the U.S. less prepared for a potential influenza pandemic.
- The H5N1 virus has already spread to multiple dairy herds and poultry farms across the U.S., with 70 human cases reported so far.
Trump Administration Terminates Moderna’s Avian Flu Vaccine Contract
President Trump’s administration has canceled a $590 million contract with biotechnology company Moderna that was intended to fund the development of an avian flu vaccine. The Department of Health and Human Services (HHS) made the announcement this week, citing concerns about the mRNA technology that would have been used in the vaccine. This decision represents a significant shift in pandemic preparedness strategy and has sparked intense debate among health officials and vaccine experts about America’s readiness for future pandemics.
HHS Communications Director Andrew Nixon explained the rationale behind the termination, stating: “After a rigorous review, we concluded that continued investment in Moderna’s H5N1 mRNA vaccine was not scientifically or ethically justifiable.” Nixon further elaborated on the administration’s position: “This is not simply about efficacy — it’s about safety, integrity, and trust. The reality is that mRNA technology remains under-tested, and we are not going to spend taxpayer dollars repeating the mistakes of the last administration, which concealed legitimate safety concerns from the public.”
Promising Clinical Results Overshadowed by Safety Concerns
The contract cancellation comes despite Moderna’s announcement of positive interim results from a Phase 1/2 study of its investigational pandemic influenza vaccine, mRNA-1018. According to company data, the vaccine demonstrated a robust immune response in approximately 300 healthy adult participants, with 97.8% achieving protective antibody titers after the second dose. The vaccine was also reported to be generally well-tolerated, with most adverse reactions being mild and not increasing significantly with additional doses.
🚨#BREAKING MAHA 🇺🇸
Moderna OFFICIALLY Loses $700M US Contract for Bird Flu Vaccine Development!Moderna OFFICIALLY ANNOUNCES that the Trump administration has canceled a major contract worth nearly $700 million for the development of its bird flu vaccine.
This decision ends a… pic.twitter.com/esAEQeAMPK
— SANTINO (@MichaelSCollura) May 29, 2025
“While the termination of funding from HHS adds uncertainty, we are pleased by the robust immune response and safety profile observed in this interim analysis of the Phase 1/2 study of our H5 avian flu vaccine and we will explore alternative paths forward for the program,” said Stéphane Bancel Chief Executive Officer of Moderna.
Despite these promising results, the Trump administration has decided to shift vaccine funding toward platforms with better-established safety profiles and more transparent data practices. The U.S. currently maintains existing vaccines against H5 viruses in its Strategic National Stockpile, though these use older technology that may not be as effective or quick to produce as mRNA-based alternatives in the event of a widespread outbreak.
Experts Warn of Pandemic Preparedness Gap
The decision has drawn criticism from numerous public health experts who worry about America’s pandemic preparedness. The H5N1 flu virus has already spread to multiple dairy herds and poultry farms across the United States, with 70 human cases reported. While the virus has not yet shown signs of easy human-to-human transmission, experts warn that it could mutate to become more transmissible, potentially leading to a pandemic if adequate vaccines aren’t available.
“This decision puts the lives and health of the American people at risk,” said Dr. Ashish Jha
The cancellation of Moderna’s contract signals a significant shift in how the administration approaches pandemic preparedness and vaccine development. While proponents of the decision cite legitimate concerns about thoroughly testing new vaccine technologies before widespread deployment, critics worry that abandoning advanced development of newer vaccine platforms could leave Americans vulnerable should a pandemic strain of avian influenza emerge. Moderna has indicated it will pursue alternative funding paths to continue development, but the timeline for potential availability of such a vaccine remains uncertain.
